Concord Biotech Ltd. (CONCORDBIO)

Date Range: 2026-03-23 to 2026-06-23 | Starting Capital: ₹100,000

Symbol-Specific Risk & Execution Parameters

These execution parameters have been optimized specifically for CONCORDBIO based on historical volatility, structural character, and friction constraints:

• ATR Stop Distance (max_stop_atr): 1.50x ATR
• Minimum Reward-to-Risk Ratio (min_reward_risk): 1.20R
• Friction Buffer Target (friction_min_target_pct): 0.03%
• Positional Holds Allowed (allow_positional_hold): True

[!WARNING]

Offline Daily Macro Data Missing: The macro and multi-horizon outlook sections were omitted because local daily price data was not found.

Executive Summary

Model Backtest & Validation Summary

To validate the conviction score recommendations, the system ran historical simulation backtests for CONCORDBIO under institutional execution assumptions:

What Changed Since Previous Report?

• Initial Run / Baseline: No previous report was found for this symbol to perform comparative validation. This report establishes the baseline parameters.

Actionable Trading Guidance

Direct Stock Setup Outlook

No active intraday setup detected for the next session.

⌥ Options Strategy Recommendation

Recommended Vehicle: Cash Equity

Reason: Highest risk-adjusted return (EV/Risk Ratio of -0.019) with consistent historical expectancy and zero options friction.

• Volatility Dashboard: Realized Vol (RV): 60.8% | Implied Vol (IV): 64.6% | IV Rank: 67.1% | IV Percentile: 86.3%
• Directional Probabilities: P(up): 10% | P(down): 10% | P(flat): 80%
• Expected Return Distribution: Median: -5.50% (10th: -12.04%, 90th: +8.66%) | Expected Move: -0.01 ATR

Expected Value (EV) Payoff Matrix:

Systematic Execution Plan (Generic Framework)

• Stop Loss: 1.5 × ATR from entry
• Profit Targets: Target 1 (1R) for 50% scale-out, trail remainder.

Expected Outcomes & Suitability

Expected 1 Month Outcome

• Bullish: 10.0%
• Neutral: 79.9%
• Bearish: 10.0%

Expected Return Range

• Median: -5.50%
• 25th percentile: -9.18%
• 75th percentile: -0.09%

Portfolio Suitability

Suitable For:

• None

Not Suitable For:

• ✗ Swing Traders
• ✗ Positional Traders
• ✗ Long-Term Growth Investors
• ✗ Income Investors
• ✗ Low Volatility Portfolios
• ✗ Growth Investors

Sector & Regime Context

• Sector: Healthcare
• Sector Strength: 8.9/10
• Relative Strength: +0.25% vs NIFTY
• Sector Rank: 6 of 19 sectors
• Structural Regime: COMPRESSION
• Tactical Setup Focus: Compression Breakout, Inside Bar Breakout, Volatility Expansion, Extended Base Breakout, Theta-Decay Trap

Conviction Score Breakdown:

• 1. Technical Setups: +0.0 / 35 (No active technical setup and no strong daily momentum structure)
• 2. Fundamentals: +5.0 / 25 (Deteriorating business growth structure (Grade D))
• 3. Sector Context: +17.8 / 20 (Sector Strength: 8.9/10 (Healthcare))
• 4. Regime & Momentum: +12.5 / 20 (Daily candle close location: +2.5 pts (50% of range), Market in low-volatility/range regime COMPRESSION: +5.0 pts, VIX is 13.5 (Low volatility/risk): +5.0 pts)

Conviction Rating System Matrix:

Fundamental Analysis & Annual Guidance

• Valuation: Trailing P/E: 53.2 | Forward P/E: N/A | PEG Ratio: N/A | Price/Book: 6.94
• Business Growth: Revenue YoY: -0.24% | Quarterly EPS: -0.37% | ROE: N/A
• Risk & Dividend: Beta: 0.51 | Dividend Yield: 0.56% | Book Value: 192.19
• Investment Grade: Grade D (Avoid)
• Recommendation: Revenue contraction signals structural business issues. High-stability defensive profile (Beta: 0.51).
• Annual Entry Guidance: No fresh capital allocation recommended.
• Annual Exit Guidance: Liquidate any existing holdings. A business with contracting revenue is mathematically a deteriorating asset.

Historical & Simulation Evidence

Direct Stock Performance (Cash Equity)

Intraday (Close at 15:20)

<div style="color: #64748b; font-style: italic;" class="low-reliability-block">

• Trades: 1 | Win Rate: 0.0% (n=1) - Exploratory | Net PnL: ₹-1,122.75
• Ending Cash: ₹98,877.25 | Max Drawdown: ₹1,122.75 (1.1%)
• Profit Factor: 0.00 | Sortino Ratio: -1.00 | Expectancy: ₹-1,122.75/trade

</div>

Positional (Hold Overnight)

• No positional trades taken.

Buy & Hold Benchmark Performance (Buy on Day 1, Hold to End)

• Strategy: Buy & Hold | Net Return: 23.63% | Net PnL: ₹23,634.66
• Ending Cash: ₹123,634.66 | Max Drawdown: ₹14,026.19 (-14.03%)
• Entry Price: ₹1067.50 | Exit Price: ₹1319.80

Performance Comparison: Buy & Hold outperformed Trading by ₹23,634.66 (steady long-term appreciation beat friction/filtering rules under the simulated period).

Signal Frequency Breakdown:

• ORB: ~0.3 signals/month (Win Rate: 0%, n=1)

Portfolio Statistics (Combined)

Advanced Statistical Inference

Performance by Setup (Cash Equity)

Strategy Backtest Performance Matrix (Futures & Options)

Historical performance of all candidate derivative, leverage, and hedged strategies over the same setups:

For granular trade logs, see CONCORDBIO_signals.csv in this folder.